Top Stories
Revolution Medicines valuation rockets past $30B as pancreatic cancer data transforms RAS market
Revolution Medicines emerged as the clear frontrunner in the pancreatic cancer space, with RASolute 302 Phase 3 data showing daraxonrasib (RMC-6236) nearly doubled median overall survival to 13.2 months versus 6.7 months for standard chemotherapy (HR 0.40; p<0.0001), according to Endpoints News. The Financial Times reported in January 2026 that Merck was in talks to acquire Revolution Medicines for approximately $30 billion, and Endpoints News noted the post-readout valuation has moved significantly higher. Daraxonrasib is a RAS(ON) multi-selective inhibitor targeting KRAS G12X, G13X, and Q61X mutations across multiple solid tumors. Revolution Medicines secures RAS(ON) leadership with best-in-class pancreatic data Standard chemotherapy faces displacement in KRAS-mutant pancreatic adenocarcinoma. The data will be presented at AACR 2026. Revolution Medicines received a Commissioner's National Priority Voucher in October 2025 for an accelerated FDA review pathway, per a Revolution Medicines press release.
Merck PD-1xVEGF bispecific matches frontrunners in NSCLC as checkpoint wars intensify
Merck unveiled first-in-human data from MK-2010 (licensed as LM-299 from LaNova Medicines for $588M upfront in November 2024), a PD-1/VEGF bispecific antibody, ahead of presentation at AACR 2026, Fierce Biotech reported. The dual-targeting approach represents Merck's attempt to defend Keytruda dominance as bispecific antibodies reshape the checkpoint inhibitor landscape. However, Merck remained tight-lipped on Phase 3 trial plans, raising questions about confidence in the differentiation profile. MK-2010 enters a competitive field where Akeso/Summit Therapeutics' ivonescimab and BioNTech/BMS's pumitamig are further ahead in clinical development. Merck validates bispecific strategy with initial MK-2010 clinical data Single-agent checkpoint inhibitors face growing obsolescence pressure. Merck must move quickly to Phase 3 to remain competitive in the PD-1/VEGF bispecific space, per Fierce Biotech.
Lilly grabs dual-payload ADC technology through CrossBridge acquisition as toxicity race heats up
Eli Lilly agreed to acquire Houston-based startup CrossBridge Bio for up to $300 million on April 14, 2026 to access its dual-payload antibody-drug conjugate platform, MedCity News reported. CrossBridge's lead candidate, CBB-120, is a TROP2-targeting ADC carrying both a TOP1 inhibitor and an ATR inhibitor designed to overcome resistance mechanisms in current single-payload ADCs, per a CrossBridge Bio press release. The EGCit linker technology enables attachment of two distinct drug payloads via orthogonal click chemistry at precisely controlled drug-antibody ratios. An IND application for CBB-120 is anticipated in 2026. Lilly secures next-generation ADC technology to compete with established players Single-payload ADC developers face technology differentiation pressure. Lilly's move signals recognition that current ADC technology may hit toxicity ceilings, requiring more sophisticated engineering approaches, according to MedCity News.
Pipeline Watch
The FDA granted Fast Track designation to daretabart (hu1418K322A), an anti-GD2 monoclonal antibody developed by Renaissance Pharma (a subsidiary of Essential Pharma), on April 14, 2026 for high-risk neuroblastoma, according to CancerNetwork. The FDA simultaneously cleared an IND for the Phase 2/3 SHINE clinical trial in relapsed or refractory high-risk neuroblastoma. The designation enables more frequent FDA interactions and eligibility for rolling review. Daretabart builds on positive Phase 2 data demonstrating an 86.0% overall survival rate, per a Renaissance Pharma press release.
Terremoto secured $108 million to advance AKT1 blockers designed to overcome toxicity challenges that have plagued PI3K/AKT pathway inhibitors, Pharmaceutical Technology reported. The company claims selective AKT1 activity reduces dose-limiting side effects while maintaining anti-tumor efficacy. Multiple Phase 2 trials are planned across solid tumor indications.
The National Cancer Institute initiated a randomized Phase 3 trial testing chemotherapy combined with immunotherapy versus immunotherapy alone in adults over 70 with advanced NSCLC, per ClinicalTrials.gov. The study addresses treatment optimization in elderly patients who often cannot tolerate aggressive combination regimens. Primary endpoint is overall survival.
AACR 2026 will feature Revolution Medicines landmark pancreatic cancer results alongside emerging ADC data from Chinese biotechs challenging Western dominance, Endpoints News previewed. The conference expects heavy focus on RAS pathway targeting after RevMed's breakthrough. Multiple Chinese companies will present ADC clinical data in competitive tumor types.
STAT reported on two converging developments: daraxonrasib's pancreatic cancer breakthrough alongside multiple other targeted approaches gaining traction in historically treatment-resistant PDAC, and new data suggesting off-the-shelf allogeneic CAR-T treatments could match autologous CAR-T efficacy in lymphoma while reducing treatment timelines from weeks to days, per STAT.
Competitive Landscape
Revolution Medicines' daraxonrasib pancreatic cancer data positions them as the clear RAS(ON) pathway leader, forcing competitors to pay premium prices for secondary assets or alternative mechanisms, per Endpoints News. Revolution Medicines commands RAS market with best-in-class data Amgen, BMS (Mirati), and others face narrower mutation-specific positioning.
| Company | RAS Asset | Development Stage | Differentiation |
|---|---|---|---|
| Revolution Medicines | daraxonrasib (RMC-6236) | Phase 3 success | RAS(ON) multi-selective (G12X/G13X/Q61X) |
| Amgen | sotorasib (LUMAKRAS) | Approved (NSCLC) | KRAS G12C only |
| BMS (Mirati) | MRTX1133 | Phase 1/2 | KRAS G12D focused |
Lilly's CrossBridge acquisition signals that current single-payload ADCs may hit toxicity ceilings, according to MedCity News. Daiichi Sankyo leads with three approved ADCs, but dual-payload approaches could leapfrog existing technology. Next-generation ADC developers gain technology advantage Single-payload ADC platforms face obsolescence pressure.
Merck's MK-2010 PD-1/VEGF bispecific entry reflects broader industry recognition that single-target checkpoint inhibitors face growing competition from multi-targeting approaches, Fierce Biotech noted. Bispecific antibody developers capture next-generation immunotherapy market Monotherapy checkpoint inhibitors lose market share to combination approaches.
Forward Looking
- Revolution Medicines acquisition talks with Merck (reported at ~$30B pre-readout) may accelerate post-Phase 3 success; AbbVie was also reported as a potential suitor, per BioSpace.
- AACR 2026 presentations will determine whether Chinese ADC companies can challenge Western market dominance in competitive solid tumor indications.
- Renaissance Pharma's Phase 2/3 SHINE trial of daretabart in relapsed/refractory high-risk neuroblastoma could position the anti-GD2 antibody for a rolling NDA submission if data support.
- Allogeneic CAR-T manufacturing advantages may finally overcome efficacy gaps, threatening autologous CAR-T market share within 24 months.